Research News and Updates

March 18, 2020

In NIH trial, selumetinib shrinks tumours, provides clinical benefit for children with NF1.

Read the full article here.

Incredible news

Approval of Koselugo (selumetinib) increases potential for successful tumor reduction in patients. This is a major milestone which could benefit over 2.5 million living with NF!! Learn more at https://www.ctf.org/news/fda-approves-first-ever-treatment-for-nf.